IRLAB Therapeutics: Rights issue outcome - Redeye

Redeye comments on IRLAB’s announcement of the outcome of its rights issue, which raised gross proceeds of SEK115.7m. While not fully subscribed, the offering was largely secured through pre-arranged underwriting commitments. We estimate that the proceeds extend IRLAB’s financial runway into H2 2026e, enables the continued development of key programs and funds further business development efforts.

Länk till analysen i sin helhet: https://www.redeye.se/research/1120131/irlab-therapeutics-rights-issue-outcome?utm_source=finwire&utm_medium=RSS